Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens epidermal growth factor receptor (EGFR), transcript variant 3
Synonyms:
ERBB; ERBB1; HER1; mENA; PIG61
Immunogen
A synthetic phospho-peptide corresponding to residues surrounding Tyr1173 of human EGF receptor was used as immunogen. The antibody detects EGFR phosphorylated on Tyrosine 1173 of the mature human isoform 1 (corresponding to Y1197 from the precursor form
Buffer
Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
Epidermal growth factor receptor (EGFR) is a 170 kDa transmembrane glycoprotein receptor tyrosine kinase that, activated by epidermal growth factor (EGF), affects cell growth and differentiation (1). Binding of EGF or TGF alpha to EGFR activates tyrosine kinase activity of the receptor (2). The carboxy terminal tyrosine residues on EGFR, Tyr 1068, Tyr 1148, and Tyr 1173, are the major sites of autophosphorylation, which occurs as a result of EGF binding (3). Once activated, EGFR phosphotyrosines Y-1068 and Y-1173 mediate the binding of Grb2 to the EGFR. Addtionally, phosphotyrosine Y-1173 is a major binding site for SHC on the EGFR (4).
Related Pathway
Adherens junction
Cytokine-cytokine receptor interaction
Delta-Notch Signaling Pathway
EGFR1 Signaling Pathway
Focal Adhesion
MAPK signaling pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
